Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.21 USD
−15.79 M USD
0.00 USD
5.96 M
About Greenwich LifeSciences, Inc.
Sector
Industry
CEO
Snehal S. Patel
Website
Headquarters
Stafford
Founded
2006
FIGI
BBG00V6PT8C7
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
10 Reasons Why $GLSI is a buy right now!1) $GLSI had 100% success preventing breast cancer recurrence over the last 6 years in their clinical trial 1 & trial 2.
2) Management team has 35+ years working together on several other successful biotech startups. They’re just repeating a proven biotech business model.
3) Executive team already
$GLSI Releases Trial Data Soon- Keep It On Your WatchlistFundamental Analysis:
Greenwich LifeSciences Inc. is a clinical-stage biopharmaceutical company that focuses on the development of a breast cancer immunotherapy treatment to prevent the recurrence of cancer following surgery. This treatment, GP2 , has been undergoing phase two clinical trials for
GLSI ready for breakout Seems to be ready for a run. Consolidating for a long time after a huge jump on their breast-cancer news from 5 to 158 in a single day. Increase of the social sentiments around this ticker. I would perhaps get an initial swing position on Monday for longer-term play and add the dips. Risk/reward is
Speculative play on $GLSIHello fellow traders and all of you beautiful people that read my analyses. If you follow the markets you know that GLSI rallied over 2,900% in one single day on hopes of a new phase of their breast cancer treatment (bit.ly). If you were in it, I have to congratulate you. That is almost 30X your mo
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of GLSI is 9.80 USD — it has increased by 5.99% in the past 24 hours. Watch Greenwich LifeSciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Greenwich LifeSciences, Inc. stocks are traded under the ticker GLSI.
GLSI stock has risen by 17.44% compared to the previous week, the month change is a −7.67% fall, over the last year Greenwich LifeSciences, Inc. has showed a −21.13% decrease.
We've gathered analysts' opinions on Greenwich LifeSciences, Inc. future price: according to them, GLSI price has a max estimate of 39.00 USD and a min estimate of 39.00 USD. Watch GLSI chart and read a more detailed Greenwich LifeSciences, Inc. stock forecast: see what analysts think of Greenwich LifeSciences, Inc. and suggest that you do with its stocks.
GLSI reached its all-time high on Dec 9, 2020 with the price of 158.07 USD, and its all-time low was 3.26 USD and was reached on Nov 4, 2020. View more price dynamics on GLSI chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
GLSI stock is 8.25% volatile and has beta coefficient of 1.34. Track Greenwich LifeSciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Greenwich LifeSciences, Inc. there?
Today Greenwich LifeSciences, Inc. has the market capitalization of 138.58 M, it has decreased by −9.23% over the last week.
Yes, you can track Greenwich LifeSciences, Inc. financials in yearly and quarterly reports right on TradingView.
Greenwich LifeSciences, Inc. is going to release the next earnings report on May 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GLSI earnings for the last quarter are −0.61 USD per share, whereas the estimation was −0.21 USD resulting in a −190.48% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Greenwich LifeSciences, Inc. earnings.
Greenwich LifeSciences, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
GLSI net income for the last quarter is −8.04 M USD, while the quarter before that showed −2.67 M USD of net income which accounts for −201.28% change. Track more Greenwich LifeSciences, Inc. financial stats to get the full picture.
No, GLSI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 25, 2025, the company has 8 employees. See our rating of the largest employees — is Greenwich LifeSciences, Inc. on this list?
Like other stocks, GLSI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Greenwich LifeSciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Greenwich LifeSciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Greenwich LifeSciences, Inc. stock shows the strong sell signal. See more of Greenwich LifeSciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.